Branded

Natroba provides a topical treatment for scabies infestations in adult and pediatric patients four years of age and older.

Apretude is the first and only long-acting injectable option for HIV prevention, the company said.

Xarelto is available as both an oral tablet and oral suspension formulation for use in children age 18 years old and younger.

Pfizer’s Xeljanz is now approved for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers.

Tezspire is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin, an epithelial cytokine.

Rinvoq provides treatment for adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers.

Cosentyx is now approved for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis, the company said.

Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals.

Molnupiravir received emergency use authorization for mild-to-moderate COVID-19 in adults.

Allergan’s Vuity is the first eye drop to treat presbyopia (age-related blurry near vision).

Eprontia provides a ready-to-use liquid medication for patients who have trouble swallowing pills.

Dyanavel XR offers treatment for patients age 6 years old and older with ADHD.